Although multiple factors might affect the utility and eligibility of PARP inhibition in patients with newly diagnosed advanced ovarian cancer, the most important ones may relate to gene alterations found during genetic blood testing, according to Melissa K. Frey, MD.
Frey, an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology and director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine, discussed how the timing of genetic testing may influence therapeutic decision-making regarding the use of PARP inhibitors in patients with advanced ovarian cancer in a conversation with CancerNetwork®. She began by highlighting that genetic counseling provides information beyond tumor causation and potential indications for other cancers as well as risk factors for family members, which may also affect treatment decision-making. Tune in here: https://www.cancernetwork.com/view/optimizing-the-timing-of-genetic-testing-in-advanced-ovarian-cancer
